Valeant Settles With Anacor for $142.5 Million

Valeant Pharmaceuticals International (NYSE: VRX  ) (TSX: VRX  ) and Anacor Pharmaceuticals (NASDAQ: ANAC  ) have reached a final $142.5 million settlement to put a series of spats to rest, including allegations of intellectual property infringement, shared confidential information, and broken contracts.

Anacor had previously announced a $100 million settlement from Valeant for issues originating from its newly acquired subsidiary Dow Pharmaceutical Sciences, but this latest announcement also includes settlement for dispute over a research and development pact with Valeant business unit Medicis Pharmaceutical.

Valeant's and Anacor's press releases both struck similarly formal tones with no comments from management, although Anacor's delved into more detail on individual issues dating back to 2004.  

Valeant has agreed to pay Anacor its settlement no later than Nov. 8.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2702841, ~/Articles/ArticleHandler.aspx, 10/31/2014 1:12:39 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement